Why the study?
Do statins reduce all-cause mortality in patients with ischaemic heart disease, and can these results be externally validated across different electronic health record databases?
Do statins reduce all-cause mortality in patients with ischaemic heart disease, and can these results be externally validated across different electronic health record databases?
This study demonstrates that analyses of electronic patient records can be independently and externally validated, showing consistent mortality benefits of statins in ischaemic heart disease across different UK databases.
Answers are grounded in this paper and cite their sources.
Statin-associated mortality reduction in IHD replicated across EHR databases; extends support for reproducible observational analyses in cardiovascular research.
OBJECTIVE: To conduct a fully independent and external validation of a research study based on one electronic health record database, using a different electronic database sampling the same population. DESIGN: Using the Clinical Practice Research Datalink (CPRD), we replicated a published investigation into the effects of statins in patients with ischaemic heart disease (IHD) by a different research team using QResearch. We replicated the original methods and analysed all-cause mortality using: (1) a cohort analysis and (2) a case-control analysis nested within the full cohort. SETTING: Electronic health record databases containing longitudinal patient consultation data from large numbers of general practices distributed throughout the UK. PARTICIPANTS: CPRD data for 34 925 patients with IHD from 224 general practices, compared to previously published results from QResearch for 13 029 patients from 89 general practices. The study period was from January 1996 to December 2003. RESULTS: We successfully replicated the methods of the original study very closely. In a cohort analysis, risk of death was lower by 55% for patients on statins, compared with 53% for QResearch (adjusted HR 0.45, 95% CI 0.40 to 0.50; vs 0.47, 95% CI 0.41 to 0.53). In case-control analyses, patients on statins had a 31% lower odds of death, compared with 39% for QResearch (adjusted OR 0.69, 95% CI 0.63 to 0.75; vs OR 0.61, 95% CI 0.52 to 0.72). Results were also close for individual statins. CONCLUSIONS: Database differences in population characteristics and in data definitions, recording, quality and completeness had a minimal impact on key statistical outputs. The results uphold the validity of research using CPRD and QResearch by providing independent evidence that both datasets produce very similar estimates of treatment effect, leading to the same clinical and policy decisions. Together with other non-independent replication studies, there is a nascent body of evidence for wider validity.
No takes yet. Share an insight, caveat, or question.
Reeves et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: